MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, FDMT had -$89,095K decrease in cash & cash equivalents over the period. -$109,618K in free cash flow.

Cash Flow Overview

Change in Cash
-$89,095K
Free Cash flow
-$109,618K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturities of marketable securit...
    • Issuance of common stock under t...
    • Stock-based compensation expense
    • Others
Negative Cash Flow Breakdown
    • Purchase of marketable securitie...
    • Net loss
    • Other assets
    • Others

Cash Flow
2025-12-31
Net loss
-140,109
Stock-based compensation expense
22,016
Vesting of common stock warrants in return for services
0
Change in fair value of derivative liability
-52
Depreciation and amortization
4,694
Amortization of right-of-use assets
2,931
Net accretion of discount on marketable securities
4,734
Prepaid expenses and other current assets
424
Other assets
4,927
Accounts payable
6,773
Accrued and other liabilities
8,152
Deferred revenue
-209
Operating lease liabilities
-3,193
Net cash used in operating activities
-109,082
Purchase of marketable securities
442,821
Maturities of marketable securities
350,384
Acquisition of property and equipment
536
Net cash used in investing activities
-92,973
Issuance of common stock upon exercise of stock options and vesting of rsus
984
Issuance of common stock under the offering program, net of issuance costs-Public Offering
0
Issuance of common stock under the offering program, net of issuance costs-Underwritten Offering
93,540
Issuance of common stock under the offering program, net of issuance costs-Atm Offering Program
9,683
Issuance of common stock - 2020 espp
1,253
Issuance of common stock under stock purchase agreement
7,500
Net cash provided by financing activities
112,960
Net decrease in cash and cash equivalents
-89,095
Cash and cash equivalents, beginning of period
149,336
Cash and cash equivalents, end of period
60,241
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Issuance of common stockunder the offering...$93,540K Issuance of common stockunder the offering...$9,683K Issuance of common stockunder stock purchase...$7,500K Issuance of common stock -2020 espp$1,253K Issuance of common stockupon exercise of...$984K Net cash provided byfinancing activities$112,960K Net decrease in cashand cash...-$89,095K Canceled cashflow$112,960K Stock-based compensationexpense$22,016K Accrued and otherliabilities$8,152K Accounts payable$6,773K Depreciation andamortization$4,694K Amortization of right-of-useassets$2,931K Maturities of marketablesecurities$350,384K Net cash used inoperating activities-$109,082K Canceled cashflow$44,566K Net cash used ininvesting activities-$92,973K Canceled cashflow$350,384K Net loss-$140,109K Other assets$4,927K Net accretion ofdiscount on marketable...$4,734K Operating leaseliabilities-$3,193K Prepaid expenses andother current assets$424K Deferred revenue-$209K Change in fair value ofderivative liability-$52K Purchase of marketablesecurities$442,821K Acquisition of property andequipment$536K

4D Molecular Therapeutics, Inc. (FDMT)

4D Molecular Therapeutics, Inc. (FDMT)